YOLFTbeta
Ascelia Pharma AB (publ)

Ascelia Pharma AB (publ)

ACE · ST · Healthcare / Biotechnology

0.58SEK+0.05 (+8.82%)

Price History

Full chart

Market Stats

Previous Close0.533
Open0.533
Day Range0.519 – 0.59
52-Week Range0.455 – 3.55
Volume539.29K
Market Cap108.16M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.46
Dividend Yield0.00%
Beta0.85
50-Day Avg0.6063
200-Day Avg2.22

About

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Magnus O. Corfitzen
  • Employees10
  • HeadquartersHyllie Boulevard 34, Malmö, Sweden, 215 32, Sweden
  • Websitehttps://www.ascelia.com

Leadership

  • Mr. Magnus O. CorfitzenChief Executive Officer · b. 1975

Financials

Income Statement

Currency: SEK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000000000
Cost of Revenue-2.51M62.00K825.00K8.72M3.89M1.05M938.00K888.00K
Gross Profit--2.51M-62.00K-825.00K-8.72M-3.89M-1.05M-938.00K-888.00K
Operating Expense-34.89M36.68M92.60M129.22M143.12M109.86M67.19M73.24M
Operating Income-24.71M-37.39M-36.74M-93.43M-137.95M-147.01M-110.91M-68.12M-74.13M
EBITDA-71.00K-37.52M-39.93M-98.91M-128.42M-132.06M-108.56M-67.69M-73.24M
Net Income-24.39M-37.13M-39.91M-98.70M-125.90M-131.22M-109.29M-80.03M-76.25M
R&D9.37M15.57M26.92M64.76M107.57M118.11M81.27M50.80M56.82M
Interest Expense18.00K33.00K013.00K77.00K48.00K14.00K7.54M5.51M

Balance Sheet

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets80.39M116.15M287.42M250.23M255.37M333.49M218.57M87.07M140.92M111.94M
Total Liabilities2.79M4.42M11.35M13.16M19.32M25.66M37.71M12.74M61.98M12.47M
Total Equity77.60M111.73M276.07M237.06M236.06M307.83M180.86M74.33M78.94M99.47M
Cash1.63M55.06M149.97M108.52M184.69M261.60M149.56M21.86M75.26M49.86M
Total Debt--146.00K215.00K1.78M1.66M484.00K1.06M25.40M1.04M
Net Debt-1.63M-55.06M-149.83M-108.30M-182.91M-259.94M-149.07M-20.80M-49.86M-48.82M

Cash Flow

Currency: SEK2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-20.96M-30.33M-36.92M-85.53M-116.56M-125.26M-126.79M-62.84M-72.25M
Investing Cash Flow-75.00M-75.00M-75.00K75.99M-38.00K-65.00K46.00K0-57.00K
Financing Cash Flow74.39M200.24M-60.00K92.72M184.87M-1.10K-936.00K115.19M48.21M
Capital Expenditure397.00K397.00K397.00K397.00K38.00K65.00K126.79M057.00K
Free Cash Flow-20.96M-30.33M-36.92M-85.92M-116.60M-125.33M-126.79M-62.84M-72.31M
FCF to OCF100.00%100.00%100.00%100.46%100.03%100.05%100.00%100.00%100.08%

Earnings

Report DateMay 15, 2019Aug 22, 2019Nov 8, 2019Feb 14, 2020May 13, 2020Aug 20, 2020Nov 5, 2020Feb 16, 2021May 12, 2021Aug 19, 2021Nov 4, 2021Feb 10, 2022May 11, 2022Aug 18, 2022Nov 4, 2022Feb 10, 2023May 11, 2023Aug 18, 2023Nov 8, 2023Feb 9, 2024May 16, 2024Aug 15, 2024Nov 7, 2024Feb 7, 2025May 16, 2025Aug 21, 2025Nov 5, 2025Feb 5, 2026
EPS Estimate--------6.49--------3.53--0.90-0.90-0.40-0.40-0.40-0.20-0.20-0.20-0.10-0.100.50
EPS Actual-0.68-0.62-0.54-1.16-0.71-1.31-0.51-1.25-1.00-0.99-0.82-1.01-0.84-0.68-0.77-1.53-1.07-1.19-0.63-0.31-0.50-0.39-0.42-0.29-0.23-0.20-0.13-0.13
Surprise-------80.74%-------56.66%--32.22%30.00%22.50%-25.00%2.50%-110.00%-45.00%-15.00%-100.00%-30.00%-126.00%
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap108.16M
Enterprise Value45.91M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.93
EPS-0.46
Book Value0.681
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-59.41M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-65.52%
Return on Assets-32.92%
Shares Outstanding133.54M
Shares Float122.17M
Beta0.85
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%